GlassScriptPhysician profile
Edmund A Freund
NPI 1740237155
$4,114.12
in general payments reported to CMS, 2019-2025
31 companies · $346 in 2025
The $346 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,171 · 2020: $219 · 2021: $29.73 · 2022: $165 · 2023: $1,011 · 2024: $1,172 · 2025: $346.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,523 · Education: $6.65.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,522.52 |
| Education | $6.65 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $623.29 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $603.78 | 2019-2025 | Mounjaro, Jardiance, Emgality |
| Pfizer INC. | $467.34 | 2019-2024 | |
| Astrazeneca Pharmaceuticals LP | $416.53 | 2019-2024 | Airsupra, Breztri |
| Boehringer Ingelheim Pharmaceuticals, INC. | $287.88 | 2019-2025 | Jardiance |
| Abbvie INC. | $287.54 | 2023-2025 | |
| Glaxosmithkline, LLC. | $273.95 | 2019-2025 | Shingrix, Arexvy, Bexsero |
| Bayer Healthcare Pharmaceuticals INC. | $187.57 | 2023-2024 | |
| Amgen INC. | $146.90 | 2019-2024 | Otezla, Repatha |
| Teva Pharmaceuticals USA, INC. | $86.56 | 2019-2020 | |
| Exact Sciences Corporation | $78.26 | 2024-2025 | Cologuard Collection Kit |
| Novartis Pharmaceuticals Corporation | $72.54 | 2019-2025 | |
| Sanofi Pasteur INC. | $67.03 | 2019 | |
| Philips North America LLC | $61.52 | 2019 | |
| Janssen Pharmaceuticals, INC | $53.62 | 2024-2025 | Spravato |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $46.96 | 2024 | Veozah |
| Abbott Laboratories | $43.57 | 2025 | Freestyle Libre 3 |
| Merck Sharp & Dohme LLC | $41.18 | 2019-2020 | |
| E.R. Squibb & Sons, L.L.C. | $36.35 | 2019-2023 | Eliquis |
| Horizon Therapeutics Plc | $32.88 | 2023 | Krystexxa |
| Lundbeck LLC | $28.31 | 2025 | Rexulti |
| Boston Scientific Corporation | $21.65 | 2020 | |
| Nevro Corp. | $20.72 | 2022 | |
| Sumitomo Pharma America, INC. | $20.15 | 2025 | Gemtesa |
| Ascend Therapeutics US, LLC | $18.00 | 2021 | |
| Dynavax Technologies Corporation | $17.49 | 2023 | Heplisav-B |
| Actelion Pharmaceuticals US, INC. | $16.82 | 2023 | Opsumit, Uptravi |
| Biogen, INC. | $15.12 | 2019 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $14.49 | 2019 | |
| Therapeuticsmd, INC. | $13.92 | 2019 | |
| Paratek Pharmaceuticals, INC. | $12.20 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Edmund Freund listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.